ERBB2 and breast cancer: Finally, based on the above described encouraging pre-clinical data of c-Src kinase and HER2 receptor co-targeting in breast cancer, Ocana and collaborators conducted a Phase II clinical trial combining dasatinib with the anti-HER2 trastuzumab and paclitaxel (Table 2).